AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02477774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARISTA
Description: According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
Study NCT00521274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 5T4
Description: Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
Study NCT00521274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
Study NCT00922558 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Evaluation of postural control
Description: Children will be measured once using a Tetra-aximetric posturography method
Study NCT00922558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural control
Description: Children will be measured once using a Tetra-aximetric posturography method
Study NCT01402180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Study NCT01402180 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT01402180 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01402180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT01402180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Study NCT04158336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is a study drug
Study NCT02979093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: All women will receive a nasal spray containing oxytocin.
Study NCT03157895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connecting
Description: Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
Study NCT01849276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given orally
Study NCT01849276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01849276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00731523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod (FTY720)
Study NCT00118508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risedronate (including placebo)
Description: risedronate 35mg weekly
Study NCT00523406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy and intravitreal triamcinolone
Description: combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
Study NCT02462941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Testing escalating doses of adenosine in pediatric heart transplant patients
Study NCT02462941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Description: (non-experimental) standard procedure
Study NCT04376606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
Study NCT04376606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
Study NCT04376606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study NCT03449316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaler technique education
Description: Teaching of inhalers use with placebo devices in real training
Study NCT04568941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Biopsy
Description: Vacuum-Assisted Biopsy
Study NCT04568941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Needle Biopsy
Description: Core Needle Biopsy
Study NCT04568941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intraoperative Excisional Biopsy
Description: Intraoperative Excisional Biopsy
Study NCT01061203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: Treatment with 75.000 SQ-T once daily
Study NCT01061203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet with no active grass component.
Study NCT02156050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two sessions of 4 hours Phototherapy treatment
Description: two sessions of 4 hours Phototherapy treatment
Study NCT02156050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two sessions of 4 hours Phototherapy treatment
Description: two sessions of 4 hours Phototherapy treatment
Study NCT00869258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, docetaxel, and capecitabine
Description: Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
Study NCT00869258 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy with gemzar
Description: Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
Study NCT00636207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
Study NCT00636207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry powder inhaler
Study NCT00523107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week
Study NCT00523107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PG2
Description: PG2 500 mg / 500 ml normal saline t.i.w. per week
Study NCT00523107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml normal saline t.i.w. per week
Study NCT01396837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RedDress Wound Care System (RD1)
Description: Weekly application. A blood based wound care treatment
Study NCT02473419 — intervention group
Intervention type: DRUG
Intervention: Vayarin
Study NCT02473419 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT02979093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: All women will receive a nasal spray containing a placebo solution.
Study NCT02979093 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional MRI scanning
Description: Study participants undergo two functional MRI scans.
Study NCT04133766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Based Nutrition Package (CNBP)
Description: The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
Study NCT02907541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QI4U learning
Description: Learners will have access to 8 QI methods modules on QI4U
Study NCT02907541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated learning
Description: Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
Study NCT02907541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QI4U and Facilitated learning
Description: Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
Study NCT03511274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene based educational film
Description: Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
Study NCT03314818 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound 3D Imaging
Description: Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism.
Study NCT02718157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC PCR and Reference Method
Description: Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
Study NCT00622284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI 1356 5mg
Description: Placebo tablet once daily
Study NCT00622284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
Description: Placebo tablets once daily
Study NCT00666276 — intervention group
Intervention type: DRUG
Intervention: linezolid (Zyvox)
Description: Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration.
Study NCT02725775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100% Florida OJ
Study NCT03464266 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF and DMPA
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study NCT03464266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study NCT02725775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Equicaloric Orange Drink
Study NCT04419623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth
Study NCT03464266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study NCT03464266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neither DMPA nor FTC/TDF
Description: The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
Study NCT03582579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Virtual Reality
Description: Action Video Game Based Training in Virtual Reality
Study NCT03582579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on a computer screen
Description: Action Video Game Based Training on a computer screen
Study NCT01677988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemotherapy
Description: 1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation.
Study NCT01677988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection
Study NCT01677988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: 1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies
Study NCT00499837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Study NCT00499837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Study NCT00665444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
Study NCT00101010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg, SC daily, start 24 hours after chemotherapy
Study NCT00101010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SC one time (24 hours after chemotherapy)
Study NCT00101010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
Study NCT00101010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 IVPB on day 1
Study NCT00101010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin hydrochloride
Description: 40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
Study NCT00101010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m\^2 oral days 1 - 5.
Study NCT00101010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: 2 mg IV, day 1
Study NCT02928874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: % COMPX (low ED vs. high ED preload)
Study NCT00622284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 5mg, once daily in the morning for 104 weeks
Study NCT00622284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
Study NCT00087607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg/day po
Study NCT00087607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b (PEG-Intron)
Description: 1.5 micrograms/kg sc weekly
Study NCT00087607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000/1200mg/day po
Study NCT00087607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly
Study NCT00916942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsaicin 8%
Description: High concentration capsaicin 8% dermal patch applied for one hour
Study NCT00916942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Description: Pre-treatment for NGX-4010
Study NCT00868608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (CMC-544)
Description: Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
Study NCT01460004 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: patella knee strap
Description: infra patella strap 100% cotton pressure is exerted immediately under the patella
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiaggregant therapy
Description: AAS 100mg/d or Clopidogrel 75mg/d
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiaggregant therapy
Description: AAS 100mg/d or Clopidogrel 75mg/d
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive therapy
Study NCT01738542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Study NCT03652597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: Subjects receive TMS on several cortical brain locations, while recording the heart rate.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demo Video
Description: Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demo Video
Description: Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.